Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Positive phase Ib trial for Alba’s celiac disease medicine
In a 21-patient cohort of celiac disease sufferers, the oral administration of AT1001 induced a significantly positive result in the trial’s primary target endpoint compared to placebo. “We
In a 21-patient cohort of celiac disease sufferers, the oral administration of AT1001 induced a significantly positive result in the trial’s primary target endpoint compared to placebo. “We
The problem of medication non-adherence adds an estimated $100 billion to healthcare spending in the US every year, according to a study from The New England Journal of
The findings, presented at the 55th annual scientific session of the American College of Cardiology, mark the first time that a statin has demonstrated a regression in artery
The study enrolled 391 patients, who were assessed after six months of therapy. Results from the study showed NM-702 was associated with a statistically significant increase in patients’
In a phase I randomized, double-blind trial of 18 healthy volunteers, results showed that, in the treated subjects, ozone-induced sputum neutrophilia was inhibited. Neutrophils are believed to play
Under the terms of the agreement, Watson will acquire all of the outstanding shares of Andrx common stock for a cash amount of $25 per share. The boards
The phase IIb data, which indicate that therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia (CLI), were released in a late-breaking clinical
The analysis showed that Vytorin (ezetimibe/simvastatin) reduced LDL cholesterol by an average of 52.5% and C-reactive protein (CRP) by an average of 31%, compared to averages of 38%
The results from the 553-patient phase III peripheral arterial disease (PAD) trial, named SIMPADICO, showed that the study did not reach the primary endpoint of change in maximal
The European phase II study will enroll 40 women and compare three doses of double blinded Proellex against open label Lupron, the current standard of care, for up